Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry.
Lieberman
Jeffrey A
JA
Javitch
Jonathan A
JA
Moore
Holly
H
D000109:Acetylcholine / Q000096:biosynthesis; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D018679:Cholinergic Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007395:Interneurons / Q000502:physiology; D009431:Neural Conduction / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009483:Neuropsychological Tests; D011570:Psychiatry / Q000379:methods* / Q000639:trends*; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
D018679:Cholinergic Agonists; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D000109:Acetylcholine